nach oben

Current Cardiology Reports

Erschienen in:

14.07.2023 | Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Venous Ethanol Ablation Approaches for Radiofrequency-Refractory Cardiac Arrhythmias

verfasst von: Stephanie Fuentes, Miguel Valderrábano

Erschienen in: Current Cardiology Reports | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In this review, we summarize the procedural approach and outcomes of venous ethanol infusion in the treatment of ventricular arrhythmias with intramural site of origin.

Recent Findings

Coronary venous ethanol infusion has emerged as a novel, safe, and effective adjunctive strategy to radiofrequency ablation of drug refractory ventricular arrhythmias with an intramural origin.

Summary

Radiofrequency catheter ablation is the first-line treatment for drug refractory ventricular arrythmias. Its success is highly dependent on the ability to reach targeted myocardium. Radiofrequency failures are common in patients with ventricular arrhythmias arising from deep intramural substrates, and those whose origin is in close proximity to vital structures such as coronary arteries or the phrenic nerve. Coronary venous ethanol infusion has emerged as a novel technique that circumvents these limitations.

Peachey H, Pedersen CT, Kay GN, et al. EHRA/HRS/APHRS Expert Consensus on Ventricular Arrhythmias. Heart Rhythm. 2014;11(10):e166–96. https://doi.org/10.1016/j.hrthm.2014.07.024.CrossRef

Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–21. https://doi.org/10.1056/nejmoa1513614.CrossRefPubMed

Tokuda M, Kojodjojo P, Tung S, et al. Acute failure of catheter ablation for ventricular tachycardia due to structural heart disease: causes and significance. J Am Heart Assoc. 2013;2(3). https://doi.org/10.1161/JAHA.113.000072.

Neira V, Santangeli P, Futyma P, et al. Ablation strategies for intramural ventricular arrhythmias. Heart Rhythm. 2020;17(7):1176–84. https://doi.org/10.1016/j.hrthm.2020.02.010.CrossRefPubMed

Stevenson WG, Tedrow UB, Reddy V, et al. Infusion needle radiofrequency ablation for treatment of refractory ventricular arrhythmias. J Am Coll Cardiol. 2019;73(12):1413–25. https://doi.org/10.1016/j.jacc.2018.12.070.CrossRefPubMed

Aziz Z, Moss JD, Jabbarzadeh M, Hellstrom J, Balkhy H, Tung R. Totally endoscopic robotic epicardial ablation of refractory left ventricular summit arrhythmia: first-in-man. Heart Rhythm. 2017;14(1):135–8. https://doi.org/10.1016/j.hrthm.2016.09.005.CrossRefPubMed

Nguyen DT, Tzou WS, Sandhu A, et al. Prospective multicenter experience with cooled radiofrequency ablation using high impedance irrigant to target deep myocardial substrate refractory to standard ablation. JACC Clin Electrophysiol. 2018;4(9):1176–85. https://doi.org/10.1016/j.jacep.2018.06.021.CrossRefPubMed

Schurmann P, Peñalver J, Valderrábano M. Ethanol for the treatment of cardiac arrhythmias. Curr Opin Cardiol. 2015;30(4):333–43. https://doi.org/10.1097/HCO.0000000000000183.CrossRefPubMedPubMedCentral

Inoue H, Waller BF, Zipes DP. Intracoronary ethyl alcohol or phenol injection ablates aconitine-induced ventricular tachycardia in dogs. J Am Coll Cardiol. 1987;10(6):1342–9. https://doi.org/10.1016/S0735-1097(87)80139-0.CrossRefPubMed

10.

Brugada P, de Swart H, Smeets L, Wellens HJ. Clinical investigation transcoronary chemical ablation of ventricular tachycardia address for correspondence and reprints. http://ahajournals.org.

11.

Neal Kay G, Epstein AE, Bubien RS, et al. Intracoronary ethanol ablation for the treatment of recurrent sustained ventricular tachycardia. 19.

12.

Verna E, Repetto S, Saveri C, Forgione N, Merchant S, Binaghi G. Myocardial dissection following successful chemical ablation of ventricular tachycardia. 13:1992.

13.

Tokuda M, Sobieszczyk P, Eisenhauer AC, et al. Transcoronary ethanol ablation for recurrent ventricular tachycardia after failed catheter ablation an update. Published online. 2011. https://doi.org/10.1161/CIRCEP.111.966283/-/DC1.CrossRef

14.

Sacher F, Sobieszczyk P, Tedrow U, et al. Transcoronary ethanol ventricular tachycardia ablation in the modern electrophysiology era. Heart Rhythm. 2008;5(1):62–8. https://doi.org/10.1016/j.hrthm.2007.09.012.CrossRefPubMed

15.

Gabus V, Jeanrenaud X, Eeckhout E, Pruvot E. Transcoronary ethanol for incessant epicardial ventricular tachycardia. Heart Rhythm. 2014;11(1):143–5. https://doi.org/10.1016/j.hrthm.2013.09.058.CrossRefPubMed

16.

Wright KN, Morley Bsbme T, Bicknell J, Bishop SP, Walcott GP, Neal Kay G. Retrograde coronary venous infusion of ethanol for ablation of canine ventricular myocardium.

17.

Baher A, Shah DJ, Valderrabano M. Coronary venous ethanol infusion for the treatment of refractory ventricular tachycardia. Heart Rhythm. 2012;9(10):1637–9. https://doi.org/10.1016/j.hrthm.2012.06.003.CrossRefPubMedPubMedCentral

18.

Kreidieh B, Rodríguez-Mañero M, Schurmann PA, Ibarra-Cortez SH, Dave AS, Valderrábano M. Retrograde coronary venous ethanol infusion for ablation of refractory ventricular tachycardia. Circ Arrhythm Electrophysiol. 2016;9(7). https://doi.org/10.1161/CIRCEP.116.004352.

19.

Okishige K, Nakamura R, Yamauchi Y, Keida T, Sasano T, Hirao K. Chemical ablation of ventricular tachycardia arising from the left ventricular summit. Clin Case Rep. 2019;7(11):2036–41. https://doi.org/10.1002/ccr3.1397.CrossRefPubMedPubMedCentral

20.

Yokokawa M, Good E, Chugh A, et al. Intramural idiopathic ventricular arrhythmias originating in the intraventricular septum mapping and ablation. Circ Arrhythm Electrophysiol. 2012;5(2):258–63. https://doi.org/10.1161/CIRCEP.111.967257.CrossRefPubMed

21.

Briceño DF, Enriquez A, Liang JJ, et al. Septal coronary venous mapping to guide substrate characterization and ablation of intramural septal ventricular arrhythmia. JACC Clin Electrophysiol. 2019;5(7):789–800. https://doi.org/10.1016/j.jacep.2019.04.011.CrossRefPubMed

22.

Komatsu Y, Nogami A, Shinoda Y, et al. Idiopathic ventricular arrhythmias originating from the vicinity of the communicating vein of cardiac venous systems at the left ventricular summit. Circ Arrhythm Electrophysiol. 2018;11(1). https://doi.org/10.1161/CIRCEP.117.005386.

23.

Loukas M, Bilinsky S, Bilinsky E, El-Sedfy A, Anderson RH. Cardiac veins: a review of the literature. Clin Anat. 2009;22(1):129–45. https://doi.org/10.1002/ca.20745.CrossRefPubMed

24.

Tavares L, Fuentes S, Lador A, et al. Venous anatomy of the left ventricular summit: therapeutic implications for ethanol infusion. Heart Rhythm. 2021;18(9):1557–65. https://doi.org/10.1016/j.hrthm.2021.05.008.CrossRefPubMedPubMedCentral

25.

Tavares L, Valderrábano M. Retrograde venous ethanol ablation for ventricular tachycardia. Heart Rhythm. 2019;16(3):478–83. https://doi.org/10.1016/j.hrthm.2018.09.010.CrossRefPubMed

26.

• Patel A, Nsahlai M, Flautt T, et al. Advanced techniques for ethanol ablation of left ventricular summit region arrhythmias. Circ Arrhythm Electrophysiol. 2022;15(8):519–29. https://doi.org/10.1161/CIRCEP.122.011017. This study delineates techniques to navigate through challenging venous anatomy when targeting LV summit ventricular arrhythmias.CrossRef

27.

Da-Wariboko A, Lador A, Tavares L, et al. Double-balloon technique for retrograde venous ethanol ablation of ventricular arrhythmias in the absence of suitable intramural veins. Heart Rhythm. 2020;17(12):2126–34. https://doi.org/10.1016/j.hrthm.2020.05.027.CrossRefPubMedPubMedCentral

28.

•• Tavares L, Lador A, Fuentes S, et al. Intramural venous ethanol infusion for refractory ventricular arrhythmias: outcomes of a multicenter experience. JACC Clin Electrophysiol. 2020;6(11):1420–31. https://doi.org/10.1016/j.jacep.2020.07.023. Findings of this study support the effectiveness of venous ethanol infusion.CrossRefPubMed

29.

• Fuentes Rojas SC, Malahjfi M, Tavares L, et al. Acute and long-term scar characterization of venous ethanol ablation in the left ventricular summit. JACC Clin Electrophysiol. Published online October 2022. https://doi.org/10.1016/j.jacep.2022.08.035. Finds of this study support the safety of venous ethanol ablation with regards to extent of lesion created by ethanol acutely and in long term follow up.

30.

Kumar S, Tedrow UB, Stevenson WG. Adjunctive interventional techniques when percutaneous catheter ablation for drug refractory ventricular arrhythmias fail. Circ Arrhythm Electrophysiol. 2017;10(2). https://doi.org/10.1161/CIRCEP.116.003676.

31.

Vergara P, Trevisi N, Ricco A, et al. Late potentials abolition as an additional technique for reduction of arrhythmia recurrence in scar related ventricular tachycardia ablation. J Cardiovasc Electrophysiol. 2012;23(6):621–7. https://doi.org/10.1111/j.1540-8167.2011.02246.x.CrossRefPubMed

32.

Acosta J, Fernández-Armenta J, Penela D, et al. Infarct transmurality as a criterion for first-line endo-epicardial substrate–guided ventricular tachycardia ablation in ischemic cardiomyopathy. Heart Rhythm. 2016;13(1):85–95. https://doi.org/10.1016/j.hrthm.2015.07.010.CrossRefPubMed

33.

Izquierdo M, Sánchez-Gómez JM, Ferrero de Loma-Osorio A, et al. Endo-epicardial versus only-endocardial ablation as a first line strategy for the treatment of ventricular tachycardia in patients with ischemic heart disease. Circ Arrhythm Electrophysiol. 2015;8(4):882–889. https://doi.org/10.1161/CIRCEP.115.002827.

34.

Tung R, Michowitz Y, Yu R, et al. Epicardial ablation of ventricular tachycardia: an institutional experience of safety and efficacy. Heart Rhythm. 2013;10(4):490–8. https://doi.org/10.1016/j.hrthm.2012.12.013.CrossRefPubMed

35.

di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2012;60(2):132–41. https://doi.org/10.1016/j.jacc.2012.03.044.CrossRefPubMed

36.

Nakahara S, Tung R, Ramirez RJ, et al. Characterization of the arrhythmogenic substrate in ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2010;55(21):2355–65. https://doi.org/10.1016/j.jacc.2010.01.041.CrossRefPubMedPubMedCentral

37.

•• Valderrábano M, Fuentes Rojas SC, Lador A, et al. Substrate ablation by multivein, multiballoon coronary venous ethanol for refractory ventricular tachycardia in structural heart disease. Circulation. Published online November 29, 2022.https://doi.org/10.1161/circulationaha.122.060882. Findings of this study highlight the effectiveness of multiballoon and multivein venous ethanol ablation of complex substrate in patients with structural heart disease.

Titel: Venous Ethanol Ablation Approaches for Radiofrequency-Refractory Cardiac Arrhythmias
verfasst von: Stephanie Fuentes
Miguel Valderrábano
Publikationsdatum: 14.07.2023
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 9/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01914-6

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Venous Ethanol Ablation Approaches for Radiofrequency-Refractory Cardiac Arrhythmias

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2023

Addressing Cardiovascular Risk Across the Arc of a Woman’s Life: Sex-Specific Prevention and Treatment

COVID-19 Vaccination and Cardiac Arrhythmias: A Review

Bempedoic Acid: A Contemporary Review of Its Pharmacology, Efficacy, and Safety Profile, Including Recent Data from the CLEAR Outcomes Clinical Trial

Update on Transcatheter Device Closure of Congenital Septal Defects

Cardio-Obstetrics: A Focused Review

Fibrates, Hypertriglyceridemia, and CVD Risk: Where Do We Stand After the PROMINENT Trial for Triglyceride Lowering?

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie